 DURHAM, N.C.--BUSINESS WIRE--Precision BioSciences, Inc. Nasdaq: DTIL a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing therapies, today announced that the Company will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022. Details for the in-person fireside chat are as follows: Date: Tuesday, September 13, 2022 Time: 4:30 PM ET Location: Lotte New York Palace Hotel The fir 